Zydus Lifesciences Ltd. received a significant regulatory boost on Friday as the U.S. Food and Drug Administration (USFDA) granted approval for its generic version of Glatiramer Acetate Injection, a medication used to manage relapsing forms of multiple sclerosis (MS). The approval marks another milestone in the company’s strategic push into complex generics and specialty pharmaceuticals. Developed in collaboration with Chemi S.p.A. and manufactured in Europe, the drug targets a U.S. market currently valued at approximately USD 719 million annually.